PUBLISHER: Grand View Research | PRODUCT CODE: 2188718
PUBLISHER: Grand View Research | PRODUCT CODE: 2188718
The global oral analgesics market size was valued at USD 22.5 billion in 2025 and is projected to grow from USD 23.3 billion in 2026 to USD 31.0 billion in 2033, at a CAGR of 4.2% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 41.2% in 2025. The market is mature, supported by continued demand for medicines used to manage acute and chronic pain, including headache, musculoskeletal pain, dental pain, arthritis, menstrual pain, and postoperative pain.
Non-opioid medicines, particularly acetaminophen/paracetamol and nonsteroidal anti-inflammatory drugs (NSAIDs), account for a major part of routine oral pain management because of their broad availability through prescription and over-the-counter channels. Recent U.S. data also show frequent use of acetaminophen, ibuprofen, and aspirin among adults, supporting continued demand for established oral pain medicines.
At the same time, opioid analgesics remain important for moderate to severe pain but face tighter safety controls due to risks related to misuse, dependence, and overdose. Regulatory focus is therefore shifting toward non-opioid pain medicines, while product development continues to focus on combination formulations, dosing convenience, safety, and longer pain relief.
Global Oral Analgesics Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global oral analgesics market report based on drug class, prescription status, formulation, distribution channel, and region: